https://www.selleckchem.com/products/unc5293.html
Across diagnostic periods, use of CurTrt increased from 15% to 51% in men aged ≥70 and 65% to 81% in men aged70years. With median five years follow-up, PCSM decreased in all patients (P.05), in the third period restricted to senior adults. In all patients NoCurTrt was associated with three-fold higher 5-year PCSM and two-fold higher OM compared to CurTrt. In high-risk PCa patients, increased use of CurTrt, greatest in senior men, was observed along with decreased PCSM and OM in both senior and younger adults. CurTrt should incre
Like
Comment
Share
